Form S-8 Ascendis Pharma A/S
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- US stock futures rise as oil pullback amplifies Fed rate-hike boost
- Oil prices extend losses as supply disruption fears ease
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Turkish Stocks Fall 6%, Triggering Market-wide Circuit Breaker - Bloomberg
Oppenheimer Upgrades Ascendis Pharma (ASND) to Outperform
September 5, 2024 6:54 AM EDTOppenheimer analyst Leland Gershell upgraded Ascendis Pharma (NASDAQ: ASND) from Perform to Outperform with a price target of $180.00.
The analyst comments "We upgrade ASND to Outperform (from Perform) and assign a $180 PT ahead of 1) Yorvipath's US launch for hypoparathyroidism (to commence by 1Q25)... More
